Pharmacoeconomics analysis of pegylated liposomal doxorubicin (Caelyx®) in the treatment of patients with metastatic breast cancer at high risk of cardiac events
Goal: to conduct the pharmacoeconomic analysis of use of pegylated liposomal doxorubicin (PLD) versus doxorubicin in patients with metastatic breast cancer at a high risk of cardiac events with prior adjuvant anthracycline therapy. Materials and methods: Markov model was developed to estimate such o...
Main Author: | I. S. Krysanov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Izdatelstvo OKI
2018-05-01
|
Series: | Качественная клиническая практика |
Subjects: | |
Online Access: | https://www.clinvest.ru/jour/article/view/33 |
Similar Items
-
Keliks (pegilirovannyy liposomal'nyy doksorubitsin) v programmnoy terapii 2-y linii metastaticheskogo raka molochnoy zhelezy
by: - -
Published: (2006-03-01) -
Place of pegylated liposomal doxorubicin in the therapy of metastatic breast cancer
by: E. V. Artamonova
Published: (2016-09-01) -
Opyt primeneniya Taksotera v kombinatsii s doksorubitsinom v kachestve khimioterapii 1-y linii u bol'nykh metastaticheskim rakom molochnoy zhelezy
by: V M Samoylenko, et al.
Published: (2006-03-01) -
Drug treatment for metastatic breast cancer
by: E. V. Artamonova
Published: (2014-08-01) -
Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx®) as Pressurized Intraperitoneal Aerosol Chemotherapy
by: Manuela Robella, et al.
Published: (2019-06-01)